Sol-Gel Clinical Trial Information

We are pleased to share updated information on the Sol-Gel clinical trial that is now recruiting participants for the topical medication to prevent the development of basal cell carcinomas in those over 18 years of age with Gorlin syndrome. If you or someone you know is interested in learning more about this clinical trial please call (717)-454-4187

The following clinical trial sites listed below are currently open and actively recruiting.

NORTHEAST

  • Dr. JiaDe (Jeff) Yu
    Harvard Medical School – Massachusetts General Hospital (MGH) – Department of Dermatology
    Anicka Lawrence | Clinical Research Coordinator
    MGH Clinical Unit for Research Trials and Outcomes in Skin (CURTIS)
    50 Staniford St. Suite 240
    Boston, MA 02114
    Tel: 617-726-5066 | Fax: 617-724-2998
    harvardskinstudies@partners.org

  • Dr. Robert Nossa
    Schweiger Dermatology P.C.
    Malgorzata Lopez
    RMA, PHP, Lead Study Coordinator, Regulatory
    60 Pompton Ave.
    Verona, NJ 07044
    Tel: 929.547.0508
    malgorzata.lopez@schweigerderm.com

  • Dr. Elizabeth Billingsley
    Penn State Hershey Medical Center
    Samantha Gettle LPN, CCRC
    Associate Clinical Research II
    Penn State Health
    500 University Drive
    Dermatology Research UPC II Room 2010
    Hershey, PA 17033
    P: (717)531-4439
    F: (717)531-5088
    sgettle2@pennstatehealth.psu.edu

  • Dr. Kristin Bibee
    The Johns Hopkins Hospital
    The Johns Hopkins Outpatient Center
    601 N Caroline St
    8th Floor, Suite 8033
    Baltimore, MD 21287
    PI: Dr. Kristin Bibee
    Research program manager: Ruizhi Wang
    Email: rwang@jhmi.edu
    Research program coordinator: Yage Sun
    Email: ysun147@jh.edu
    Phone: 410-502-7546

SOUTHEAST

  • Dr. Cheryl Hull
    Northwest Arkansas Clinical Trials Center, PLLC
    599 S. Horsebarn Rd.
    Suite 200
    Rogers, AR 72758Briana Tedford, B.S.
    Clinical Research Coordinator
    Northwest Arkansas Clinical Trials Center, PLLC
    599 S. Horsebarn Rd.
    Suite 200
    Rogers, AR 72758
    Phone: (479) 876-8205 Ext. 4
    Fax : (479) 876-8049
  • Dr. James Grichnik
    Lucy Lam RN, MSMS, CCRC
    Sr. Clinical Research Associate
    University of South Florida | Dept of Dermatology
    13330 USF Laurel Drive, Tampa FL 33612
    P:813-974-8249
    E:llam@usf.edu

SOUTHWEST

  • Dr. Timothy Rodgers
    North Texas Center for Clinical Research
    3880 Parkwood Blvd Suite 102
    Frisco, TX 75034Keisha Neal
    Chief Operating Officer
    (214) 618-0220
    (214) 783-5185

MIDWEST

  • Dr. Steven Kempers
    Minnesota Clinical Study Center
    119 14th St NW Suite 250
    New Brighton, MN 55112 USA
    PI: Steven Kempers
    Contact Business Phone Number: 763-571-4200Jenjira Skrei, BA, CCRC
    Research Manager
    Minnesota Clinical Study Center
    119 14th Street NW, Suite 250
    New Brighton, MN 55112
    office: 763-571-4200
    fax: 763-502-2975
  • Dr. Jorge Garcia-Zuazaga
    Apex Clinical Research Center
    29111 Cedar Road
    Mayfield Heights, OH 44124Brooke Glivar, LPN, CCRC |Research Site Manager
    Apex Clinical Research Center, LLCApex Skin Corporate Office
    29111 Cedar Road
    Mayfield Heights, OH 44124
    Cell: 330-933-2180
    Office: 440-940-APEX

  • Dr. Mio Nakamura
    University of Michigan Medicine
    Clinical Research Manager – Department of Dermatology
    1618 Taubman Center
    1500 E Medical Center Dr.
    Ann Arbor, MI 48109
    PI: Dr. Mio Nakamura
    Coordinator contact: Nicole Mahn
    Email – Dermtrials@med.umich.edu
    Phone 734-232-0562

WEST

  • Dr. Sunil Dhawan
    Center for Dermatology Clinical Research, Inc.
    2557 Mowry Ave Suite 34
    Fremont, CA, USA 94538
    Leanne Saud MA
    Clinical Research Coordinator
    Center for Dermatology, Clinical Research, Inc.
    2557 Mowry Ave, Ste 34
    Fremont, CA 94538
    Phone: 510-797-0140×5
  • Dr. Kavita Sarin
    Dom Mitchell – Clinical Research Coordinator
    Pronouns: she|her|hers
    Clinical Research Coordinator
    Stanford University School of Medicine – Department of Dermatology
    Stanford Skin Innovation and Interventional Research Group (SIIRG)
    455 Broadway St. Discovery Hall 1st Fl., Redwood City, CA 94063, MC 8843
    email: domcm@stanford.edu | phone: (650) 721-7192 | fax: (650) 498-5908
  • Dr. Michelle Aszterbaum
    Dermatology Center of Newport
    360 San Miguel Dr Suite 406,
    Newport Beach, CA 92660
    Hannah Walton
    Study Coordinator
    Cell Phone: (203) 564-0030
    Email address: hew2018@gmail.com

Below are the cities / states where Sol-Gel is in the process of activating sites. Currently, we are not able to provide detailed contact information.  There is no guarantee that these locations will be activated as contracts are still being negotiated.

  • New Haven, Connecticut
  • Durham, North Carolina
  • Portland, Oregon

For more information on this clinical trial, including on inclusion and exclusion criterion, please see the following resources:

Questions about Gorlin syndrome that are not related to this clinical trial should be directed to info@gorlinsyndrome.org or call 267-689-6443

Further information on this trial will be provided as soon as it becomes available.

Please consider becoming a hero to the Gorlin syndrome community by participating in this clinical trial.

Thank You

Dear Gorlin Syndrome Alliance Community,

Please allow us to introduce to you an opportunity to enroll in a clinical study to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. If you meet the criteria for this study, you will be expected to apply the medication to your face twice a day for one year (12 months). This is a double-blind study which means that neither you or the clinical investigator at the trial site will know if you are applying the drug or a placebo. The number of new BCCs that develop will be monitored in all
participants.

Patidegib Gel 2% was investigated in a clinical study in the past and while not meeting FDA success criteria, it was clearly proven that it reduced the total number of new facial BCC by 40% compared to placebo in those with the PTCH1 mutation and with a high burden of BCCs.

The study is sponsored by Sol-Gel Technologies, an innovative dermatology pharmaceutical company known for pioneering topical drugs focused on both common and rare skin conditions such as in this case Gorlin Syndrome. Sol-Gel has contracted Premier Research, a top global clinical research organization (CRO) dedicated to helping transform lifechanging ideas and breakthrough science into new medical treatments in the pharmaceutical industry.

We are delighted for this opportunity to partner and collaborate with you as individuals, and a community as a whole, with the goal of improving the lives of those who are impacted and their loved ones, in further clinical research by developing an innovative treatment option for Gorlin Syndrome.

Kind Regards,

Your Sol-Gel/Premier Research Study Team

For information on all clinical trials, go to clinicaltrials.gov.